We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

While Rheonix intends to apply this proprietary microarray technology to improve SNP detection, the technology is broadly applicable to meet the need for high volume production of high quality/low density microarrays and therefore, has licensing potential for use in multiple research and clinical applications. Together, these new technology components will allow Rheonix to produce higher quality and more accurate diagnostic results.

“We have integrated all of the key components for molecular diagnostics into a compact, automated platform – raw sample prep, molecular amplification and analysis,” said Tony Eisenhut, President of Rheonix. “The addition of the Hy-Fi Microarray to our system provides an accurate, easy to use end-point analytical tool, with the added significant benefit of low production costs for Rheonix and potential partners.”

Rheonix’s novel microarray production technology produces DNA and RNA, as well as protein, spots for an entire array in a single print, while simultaneously controlling for spot morphology and reducing array-to-array variation of the spots, thus ensuring the reproducibility of the microarray results. Using this technology, Rheonix has created Hy-Fi Microarrays, which could provide more accurate results than traditional microarrays. The Hy-Fi Microarray is further improved with the use of Locked Nucleic Acids (“LNAs”) under license from Exiqon A/S for SNP assays where the LNA’s improve the fidelity of the base pairing to exclude non-specific base pair hybridization. LNAs provide a high signal-to-noise ratio, making the microarray’s results easier to interpret. The Rheonix microarray production process is powerful, adaptable and scalable, enabling benefits for both Rheonix and potential partners.

Rheonix has initially configured the system for its own high volume microarray printing; however, it can be easily adjusted for custom microarray production using the same processes. The system’s components are user-friendly and robust, providing long service life to the research lab or production environment at a reasonable cost. Together, with the increased accuracy of results and low cost, these technology components will bring great value to Rheonix.